<DOC>
	<DOCNO>NCT01974687</DOCNO>
	<brief_summary>This multi-part study evaluate safety , tolerability , pharmacokinetics ( PK ) MK-3682 ( IDX21437 ) healthy participant participant infect HCV genotype ( GT ) 1-GT6 . The effect food PK MK-3682 evaluate . The antiviral activity MK-3682 also assess HCV-infected participant .</brief_summary>
	<brief_title>Single Multiple Dose Study MK-3682 ( IDX21437 ) Healthy Hepatitis C Virus ( HCV ) -Infected Participants ( MK-3682-001 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>All Participants : childbearing potential must agree use double method birth control ( one must barrier ) Screening least 90 day last dose study drug must consume grapefruit grapefruit juice within 7 day Day 1 throughout study HCV Participants : document clinical history compatible chronic hepatitis C. receive directacting antiviral treatment hepatitis C infection HCV Genotype 1 , 2 , 3 , 4 , 5 6 All Participants : pregnant breastfeeding coinfected hepatitis B virus ( HBV ) and/or human immunodeficiency virus ( HIV ) . decompensated liver disease clinically significant medical condition laboratory abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatitis C virus</keyword>
	<keyword>HCV</keyword>
</DOC>